MagForce AG Release: Enrollment Of The First Patient In The MF 1001 Glioblastoma Study At The Muenster University Clinic
3/31/2014 9:54:14 AM
BERLIN, March 31, 2014 (GLOBE NEWSWIRE) -- MagForce AG (Frankfurt, Xetra: MF6), a leading medical technology company in the area of nanotechnology which focuses on oncology, today announced the enrollment of the first patient in the MF 1001 clinical study. MF 1001 is an open-label, randomized, controlled clinical trial assessing the efficacy and safety of NanoTherm® therapy as monotherapy and in combination with radiotherapy compared to radiotherapy alone in glioblastoma patients at first relapse. During NanoTherm® therapy, superparamagnetized iron oxide nanoparticles are injected into the tumor and then heated in the alternating magnetic field of the NanoActivator® in order to kill the tumor cells.
Help employers find you! Check out all the jobs and post your resume.
comments powered by